In this episode, we speak with Alan Nafiiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.

Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.

To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.  

Things mentioned:

Additional Materials: 

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Arctoris COO Tom Fleming talks about automation and building a small molecule discovery platform

In this episode, our guest Assistant Prof. Tim Jenkins talks about snakebites and how to use AI to design broadly neutralising antibodies against venoms. Tim takes us through his experience at Milner Therapeutics Institute and shares his passion and vision for connecting academia and startups/industry players. In the second half of this talk, Tim explains the complexity in the venom domain and the challenges that lie ahead for the commercialisation of antivenom antibodies. 

PS: Recently, with InstaDeep, Tim has posed a snake antivenom challenge as part of the largest hackathon in Africa.

In episode 4, Murat talks with Andrew C. R. Martin, Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools!

Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as abYmod and abYdraw.  

At the end of the talk, the discussion moves into developability (stability and Immunogenicity).

To be an abYdraw beta tester contact Andrew Martin. 

Future of Drug Discovery Episode #3

We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics.

- Changing role of bioinformatics from assisting to being the main driver in biologics discovery

In this episode, Murat talks with Ryan Kelly about Abveris (employee #3) and how to run 100+ discovery campaigns against challenging targets.

FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery